Future Science Group Future Science Group

In this interview, we spoke to John Chappell, Senior Global Scientific Support Manager at Gyros Protein Technologies (Uppsala, Sweden) about his experience working with the Gyrolab platform for oligonucleotide assays. John discusses the advantages of using Gyrolab for oligo quantification in biological fluids and shares his thoughts on the next steps for these assays.

In the fifth episode of The New Frontier podcast, we're joined by Paul Byrne, Senior Director of Genomics from ProtaGene (MA, USA). Paul describes his experience working with qPCR vs digital and digital droplet PCR assays and advises on their pros and cons, as well as when it's best to use each. We discuss how these assays can be optimized for cell and gene therapy targets and get a peek into the tips and tricks he's picked up over his 30 years of experience.

In this episode of The New Frontier podcast, we're joined by Daniel Schulz-Jander, Senior Director of Mass spectrometry Bioanalysis at QPS Netherlands (Groningen). Daniel explains how he uses immune-precipitation and immunoaffinity LC–MS techniques for his work relating to macromolecular pharmaceuticals like gene therapies, as well as their benefits and challenges. Daniel also covers bottom-up, middle-down and top-down approaches and their suitability for his work in clinical support versus research and discovery.

Breaking down barriers for women in tech: an interview with Tina Marshall by Future Science Group

What disparities exist in cancer screening and how does this impact patient outcomes? Listen to our latest podcast episode with Kilan Ashad-Bishop (American Cancer Society) to find out about the intersection between science, health, and society.

AI-driven early disease detection: an interview with Jim Kean by Future Science Group